Bioventix PLC is a leading biotechnology company, representing values of innovation, excellence, and integrity. With a strong commitment to quality and scientific advancement, Bioventix is dedicated to delivering high-quality products and services in the field of medical diagnostics. The company's corporate philosophy revolves around sustained growth, strong customer relationships, and long-term shareholder value. Bioventix PLC aims to make impactful contributions to the healthcare industry through the development of novel and highly specific antibodies, leading to improved diagnostic testing capabilities. Through its dedication to ethical business practices and cutting-edge research, Bioventix PLC continues to be a trusted and influential player in the biotech sector.

Bioventix PLC is primarily present in the United Kingdom, where it is headquartered. As a global company, Bioventix also has a significant presence in other regions around the world. With a strong international footprint, the company has operations in various countries, including the United States, Europe, and Asia. Its expanded reach allows Bioventix to serve a diverse customer base and capitalize on growth opportunities in different markets. With its commitment to innovation and expertise in the healthcare sector, Bioventix PLC continues to expand its presence and make a positive impact on the global stage.

Bioventix PLC has achieved several significant milestones. Some notable achievements include developing and commercializing a range of high-quality antibodies for use in the diagnostics market. These antibodies have gained widespread recognition and are widely used by major diagnostics companies globally. Additionally, Bioventix PLC has successfully established long-term partnerships and licensing agreements with key players in the industry. The company's innovative products and reliable services have played a pivotal role in enhancing diagnostic accuracy, improving patient outcomes, and ultimately driving growth and profitability for both Bioventix PLC and its partners.

Bioventix PLC is a renowned biotechnology company based in the United Kingdom. Founded in 2003, Bioventix specializes in the development and supply of high-affinity monoclonal antibodies for use in clinical diagnostics. With a strong focus on the creation of innovative and valuable products, Bioventix has established itself as a leader in the field. The company's success can be attributed to its dedicated team of talented scientists and its commitment to delivering accurate and reliable diagnostic solutions. Bioventix PLC continues to grow and expand its portfolio of products, aiming to contribute to advancements in healthcare and improve patient outcomes.

Some of the main competitors of Bioventix PLC in the market include Abcam Plc, Novartis AG, and Roche Holding AG.

Bioventix PLC is primarily active in the biotechnology and pharmaceutical industries.

The business model of Bioventix PLC revolves around the development and supply of high quality antibodies used in the in vitro diagnostics market. As a leading biotechnology company, Bioventix specializes in the creation of monoclonal antibodies that can accurately detect specific molecules in blood samples. These antibodies are crucial for various diagnostic applications, including medical testing for conditions like thyroid disorders, vitamin deficiencies, and hormone-related diseases. With its expertise in antibody development and a strong emphasis on product quality, Bioventix PLC has established itself as a trusted provider in the diagnostics industry, catering to the needs of healthcare professionals and patients worldwide.

P/E-talet för Bioventix är 16,89.

Det Bioventix KUV är 10,40.

AlleAktien Qualitätsscore för Bioventix är 9/10.

förväntade Bioventix omsättningen är 14,65 Mkr. GBP.

förväntade Bioventix vinst är 9,02 Mkr. GBP.

Bioventix PLC specializes in the development of highly specialized antibodies for diagnostic, pharmaceutical research, and development. The company's business model is based on the production and sale of antibodies for disease diagnostics and analysis of blood samples for biomedical research. Bioventix provides antibodies for diagnostic tests, such as Troponin I, to detect biomarkers for heart conditions. They also provide antibodies for Vitamin D tests. In the pharmaceutical sector, Bioventix develops antibodies for cancer research and BNP antibodies for heart disease treatment. The company focuses on manufacturing and selling specialized antibodies, serving diagnostic companies. Their advantage lies in developing antibodies in limited quantities, providing precise and reliable results. They have an experienced team and extensive antibody library for efficient production. Overall, Bioventix has a successful business model and is expected to continue thriving in the market.

Bioventix delar ut en utdelning på 1,26 GBP fördelad över utbetalningar per år.

Utbytet kan för närvarande inte beräknas för Bioventix eller så distribuerar bolaget inget utbyte.

ISIN för Bioventix är GB00B4QVDF07.

WKN för Bioventix är A113DD.

Ticker-symbolen för Bioventix är BVXP.L.

Under de senaste 12 månaderna betalade Bioventix en utdelning på 1,55 GBP . Detta motsvarar en direktavkastning på ungefär 5,39 %. För de kommande 12 månaderna förväntas Bioventix betala en utdelning på 1,81 GBP.

Aktiens direktavkastning för Bioventix är för närvarande 5,39 %.

Bioventix betalar ut dividenden kvartalsvis. Denna distribueras under månaderna maj, december, maj, december.

Bioventix betalade utdelning varje år under de senaste 13 åren.

För de kommande 12 månaderna förväntas utdelningar uppgå till 1,81 GBP. Detta motsvarar en utdelningsavkastning på 6,30 %.

Bioventix tilldelas sektorn 'Hälsa'.

För att få den senaste utdelningen från Bioventix den 2024-11-21 på 0,87 GBP var du tvungen att ha aktien i ditt depå innan ex-dagen den 2024-11-07.

Utdelningen av den senaste dividenden skedde den 2024-11-21.

Under år 2024 delade Bioventix ut 1,52 GBP i form av utdelningar.

Utdelningarna från Bioventix betalas ut i GBP.